Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct;54(10):2584-94.
doi: 10.1007/s00125-011-2249-7. Epub 2011 Jul 28.

Identification of an Intracellular Metabolic Signature Impairing Beta Cell Function in the Rat Beta Cell Line INS-1E and Human Islets

Affiliations

Identification of an Intracellular Metabolic Signature Impairing Beta Cell Function in the Rat Beta Cell Line INS-1E and Human Islets

I Goehring et al. Diabetologia. .

Erratum in

Abstract

Aims/hypothesis: Chronic hyperglycaemia promotes the progressive failure of pancreatic beta cells in patients with type 2 diabetes mellitus, a clinically highly relevant phenomenon known as glucotoxicity. The intracellular metabolic consequences of a chronically high availability of glucose in beta cells are, as yet, poorly understood in its full complexity.

Methods: An unbiased metabolite profiling analysis (GC-time-of-flight-MS) was used to identify the time course of core metabolite patterns in rat beta cell line INS-1E during exposure to high glucose concentrations and its relation to insulin expression.

Results: We report here that pentose phosphate pathway (PPP) metabolites accumulate remarkably during chronic but not acute glucose treatment, indicating altered processing of glucose through the pentose phosphate pathway. Subsequent functional studies in INS-1E cells and human islets revealed that a disturbance in this pathway contributes to decreases in insulin gene expression and a lack of glucose-stimulated insulin secretion. These effects were found to depend on the activation of extracellular-regulated-kinase (ERK1/2). Long-term inhibition of 6-phosphogluconic acid dehydrogenase resulted in accumulation of PPP metabolites, induced ERK1/2 activation independently of high glucose and impaired beta cell function. In turn, inhibition of ERK1/2 overstimulation during chronic glucose exposure partly inhibited metabolite accumulation and restored beta cell function.

Conclusions/interpretation: Based on unbiased metabolite analyses, the data presented here provide novel targets, namely the inhibition of PPP metabolite accumulation towards the therapeutic goal to preserve and potentially improve beta cell function in diabetes.

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles

References

    1. J Clin Invest. 1986 Mar;77(3):908-15 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1973;276(2):235-41 - PubMed
    1. Endocr Rev. 2008 May;29(3):351-66 - PubMed
    1. FEBS Lett. 2007 Jul 31;581(19):3743-8 - PubMed
    1. Science. 1955 Oct 28;122(3174):834 - PubMed

Publication types

MeSH terms

Substances

Feedback